The atopic dermatitis (AD) market is facing increased growth, with a projected market value of $16.7bn by 2030 for the 7 major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), according to GlobalData. This expansion is expected to be driven by the increasing global prevalence of AD and advancements in clinical trials. Although the availability of standard treatments such as topical corticosteroids and antihistamines may improve the symptoms of AD patients, there is a need for more effective and sustainable therapies. Innovative therapies currently undergoing clinical trials include B- and T-lymphocyte attenuator (BTLA) inhibitors, OX40 inhibitors, bacterial therapies, and nuclear transport modifiers (NTMs), all of which have shown promise in addressing this unmet need. Pharmaceutical companies could take advantage of the opportunities presented by the current trends in AD trials and invest in R&D, establish collaborations, and adopt patient-focused strategies to drive growth in the AD field.
The current treatment paradigm for AD involves the use of topical corticosteroids, moisturisers, antihistamines, and recently approved interleukin inhibitors, Janus kinase (JAK) inhibitors, and phosphodiesterase (PDE) 4 inhibitors. While these are the standard of care, they often offer only temporary relief and have been associated with potential side effects. This limitation highlights the need for the development of therapies that are both more effective and have a longer-lasting impact on patients’ quality of life. Such innovative therapies include biologics, JAK inhibitors, PDE4 inhibitors, BTLA inhibitors, and OX40 inhibitors, which offer targeted and personalised approaches to AD care.
The AD market is expanding rapidly, affecting a significant portion of the global population. According to GlobalData, 781 million patients within the 7MM had AD in 2020, and this number is expected to grow. GlobalData forecasts a market valuation of $16.7bn by 2030, which reflects the high demand for effective AD treatments. The market growth drivers include increased awareness, more accurate diagnosis, and technological advancements in treatment options. As expected, the investment opportunities within the AD landscape seem to be exciting, and pharmaceutical companies seeking to expand their presence in the AD market should invest in the R&D of innovative therapies through forming strategic alliances. To further understand patient needs, pharmaceutical companies also need to contact patient advocacy groups, which will help them in future decision-making upon treatment developments.
Furthermore, by collaborating with academic and research bodies, pharmaceutical companies can also benefit as the development process can be accelerated, while patient-centric initiatives can assist pharmaceutical companies in identifying the strengths and weaknesses of their competitors. Partnerships and licensing deals with biotech firms developing promising drug candidates can also be a strategic move to secure a competitive advantage over other competitors. Such deals have included Regeneron’s and Sanofi’s alliance which has been a successful example of companies that have invested in innovative AD treatments, eventually marketing Dupixent (dupilumab) for moderate to severe AD cases. The development of Dupixent illustrates the rewards offered by such investments, as its total sales for AD only are expected to reach $6.2bn by 2030, according to GlobalData. This further showcases the exciting potential within the AD market.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData